Zuellig Pharma Executive and Leadership Team

Yan Ann Tan, the Chief Executive Officer at Zuellig Pharma, directs the overarching strategic vision for the organization across the Asian healthcare landscape. By overseeing the integration of distribution, digital, and commercial services, the Chief Executive Officer ensures the company maintains a competitive edge in complex regional markets. This leadership role involves constant collaboration with the Board to drive sustainable growth and operational excellence. Yan Ann Tan prioritizes the expansion of healthcare access, ensuring that the company meets the evolving needs of patients and partners alike. Through rigorous oversight of corporate governance and market expansion initiatives, the Chief Executive Officer secures the long-term stability of the enterprise. Tan maintains a focus on innovation, pushing the organization to adopt advanced technologies that streamline supply chain efficiency and enhance service delivery across diverse geographic territories.

June Kum, the Chief Financial Officer at Zuellig Pharma, governs the financial health and fiscal strategy of the organization. Overseeing capital allocation, financial reporting, and risk management, the Chief Financial Officer ensures that the company maintains the necessary liquidity to support its expansive healthcare services. This leadership role involves working closely with the executive team to evaluate investment opportunities and monitor the financial performance of various business units. June Kum drives the development of long-term financial models that align with the company's growth objectives in the Asian market. By implementing rigorous internal controls and financial oversight, the Chief Financial Officer protects the assets of the organization while fostering transparency. Kum maintains a focus on fiscal discipline, ensuring that the company remains well-positioned to navigate economic fluctuations while continuing to invest in digital and commercial service capabilities.

Andrew Khoo, the Chief Financial Officer, & Brunei (Malaysia) at Zuellig Pharma, manages the financial operations and fiscal strategy specifically for the Malaysia and Brunei markets. Overseeing regional financial planning, budgeting, and compliance, the Chief Financial Officer, & Brunei (Malaysia) ensures that these specific territories maintain strong financial performance. This role involves working with local leadership to optimize resource allocation and monitor the profitability of regional distribution services. Andrew Khoo drives the implementation of financial controls that support the company's growth objectives in these key markets. By analyzing regional economic trends and financial data, the Chief Financial Officer, & Brunei (Malaysia) provides insights that inform strategic decision-making. Khoo maintains a focus on fiscal stability, ensuring that the company's operations in Malaysia and Brunei remain financially sound and capable of supporting the broader organizational goals of the company.

Aylie Widjaja, the Chief Operating Officer at Zuellig Pharma, manages the daily execution of healthcare distribution and logistics services. Overseeing the complex supply chain infrastructure, the Chief Operating Officer ensures that pharmaceutical products reach healthcare providers with maximum efficiency and safety. This role requires constant coordination with regional teams to optimize inventory management and warehouse operations across the Asian market. Aylie Widjaja drives the implementation of standardized operational protocols that reduce costs while increasing service reliability for clients. By monitoring performance metrics and operational workflows, the Chief Operating Officer identifies opportunities for process improvement and resource allocation. Widjaja maintains a commitment to operational excellence, ensuring that the company supports the healthcare needs of the region through robust, scalable, and highly responsive logistics frameworks that adapt to the unique demands of the pharmaceutical industry.

Yvonne Cheah, the Chief Operating Officer, Clinical Trial Support at Zuellig Pharma, directs the specialized operations required for clinical trial logistics and support services. Overseeing the end-to-end management of clinical trial supplies, the Chief Operating Officer, Clinical Trial Support ensures that research initiatives receive the necessary materials with precision and regulatory compliance. This role involves coordinating with pharmaceutical partners to facilitate the seamless execution of trials across various Asian markets. Yvonne Cheah drives the implementation of specialized logistics protocols that meet the stringent requirements of clinical research. By optimizing the supply chain for sensitive medical products, the Chief Operating Officer, Clinical Trial Support enhances the reliability of the company's clinical support services. Cheah maintains a focus on operational quality, ensuring that the company provides the infrastructure needed to accelerate medical research and improve patient outcomes through efficient trial support.

Marc Franck, the President of Korea Companies at Zuellig Pharma, leads the strategic direction and operational management of the company's business entities within the Korean market. Overseeing the growth and development of these regional operations, the President of Korea Companies ensures that the company effectively serves the local healthcare sector. This role involves managing relationships with key stakeholders and driving the implementation of corporate strategies tailored to the Korean market. Marc Franck drives the expansion of the company's service offerings, ensuring that the organization remains a leader in the local healthcare industry. By coordinating with the broader executive team, the President of Korea Companies aligns regional activities with the global mission of the company. Franck maintains a focus on market leadership, ensuring that the company's operations in Korea remain competitive, innovative, and fully integrated into the company's regional network.

Luiz Enriquez, the Group Chief Technology Officer & Chief Information Security Officer, Caio at Zuellig Pharma, architects the digital infrastructure and cybersecurity framework for the entire organization. Overseeing the development of advanced digital platforms, the Group Chief Technology Officer & Chief Information Security Officer, Caio ensures that all data systems remain secure and compliant with regional healthcare regulations. This role involves leading the digital transformation strategy to enhance service delivery and operational efficiency across the company's diverse portfolio. Luiz Enriquez drives the adoption of cutting-edge technologies that support the company's mission of improving healthcare access. By managing the security posture of the enterprise, the Group Chief Technology Officer & Chief Information Security Officer, Caio mitigates risks associated with digital threats. Enriquez maintains a focus on innovation, ensuring that the technological foundation of the company remains robust, scalable, and capable of supporting future growth.

Avraham Raz, the Vice President Commercial Excellence and Chief Of Staff at Zuellig Pharma, manages the strategic alignment of commercial initiatives and internal executive operations. Overseeing the development of commercial strategies, the Vice President Commercial Excellence and Chief Of Staff ensures that the company effectively communicates its value proposition to healthcare partners. This role involves coordinating cross-functional projects that drive market penetration and revenue growth. Avraham Raz drives the execution of commercial excellence programs that optimize sales performance and customer engagement across the region. By serving as a key advisor to the executive leadership, the Vice President Commercial Excellence and Chief Of Staff facilitates efficient decision-making and organizational alignment. Raz maintains a focus on strategic growth, ensuring that the company's commercial efforts remain competitive and responsive to the evolving needs of the healthcare industry in Asia.

Avi Raz, the Vice President Commercial Excellence and Chief of Staff, Zuellig Pharma Commercialization at Zuellig Pharma, leads the commercialization efforts for the company's specialized service offerings. Overseeing the go-to-market strategy for new commercial services, the Vice President Commercial Excellence and Chief of Staff, Zuellig Pharma Commercialization ensures that the company captures market share through targeted outreach and service innovation. This role involves managing the operational integration of commercialization projects to ensure they align with the broader corporate mission. Avi Raz drives the implementation of best practices in commercial excellence to enhance the company's market position. By coordinating internal resources and supporting executive initiatives, the Vice President Commercial Excellence and Chief of Staff, Zuellig Pharma Commercialization facilitates the successful launch of new healthcare solutions. Raz maintains a focus on growth, ensuring that the company's commercialization efforts remain effective and aligned with regional healthcare demands.

Pucknalin Bulakul, the Chief Operations Officer at Zuellig Pharma, directs the operational strategy for specific service lines to ensure high-quality delivery of healthcare solutions. Overseeing the efficiency of internal processes, the Chief Operations Officer ensures that the company maintains high standards of service across its distribution and commercial operations. This role involves leading initiatives to streamline workflows and improve the overall effectiveness of the company's service delivery model. Pucknalin Bulakul drives the adoption of operational improvements that enhance the company's ability to meet the needs of healthcare providers. By monitoring operational performance and identifying areas for optimization, the Chief Operations Officer supports the company's commitment to excellence. Bulakul maintains a focus on operational scalability, ensuring that the company's processes remain robust and capable of supporting the growing demand for healthcare services across the Asian region.